Wed, May 29, 9:19 PM (295 days ago)
REMSLEEP HOLDINGS, INC. filed an amended 10-Q for the quarter ended March 31, 2024, to correct the number of outstanding shares. Key financial highlights include: - **Revenue**: Declined to $57,881 from $85,655 year-over-year. - **Net Loss**: Increased to $252,580 from $226,259. - **Cash Flow**: Operating activities used $113,475 in cash, an improvement from $144,023. Cash balance increased slightly to $730,625. - **Liabilities**: Total liabilities rose to $481,428 from $275,614, driven by a new convertible note and increased derivative liabilities. - **Equity**: Stockholders' equity decreased to $678,120 from $930,700, primarily due to net loss. - **Operating Expenses**: Decreased across most categories, with notable reductions in professional fees and compensation. - **Future Operations**: Company anticipates FDA approval for its DeltaWave product by Q3 2024, which is critical for future revenue growth. The amendment had no impact on other financials, focusing only on correcting the share count.